STX11

Across TCGA pan-cancer cohorts, STX11 mass-spec protein is linked to patient survival in 8 of 34 cancer types, making it a survival-associated STX11 data layer compared with 26 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher STX11 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated STX11 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and HNSC show a favorable association.

CCRCC, HNSC, and GBM are the cancer types where STX11 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	II,III,IV	0.773	0.348	.002	21	view →
HNSC	OS	Median	II,III,IV	0.784	0.640	.035	20	view →
GBM	DFS	Quartile	All	0.568	0.884	.001	19	view →
PDAC	DFS	Tertile	III,IV	0.968	0.386	.006	8	view →
COAD	DFS	Median	IV	0.493	0.944	.031	6	view →
OV	DFS	Median	All	1.000	0.868	.037	4	view →
LUAD	OS	Quartile	II,III,IV	0.299	0.792	.015	3	view →
LSCC	DFS	Tertile	All	0.852	0.389	.048	2	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

STX11–CCRCC (DFS)

Open the CCRCC breakdown →